Prevalence of cancer in Parkinson's disease related to R1441G and G2019S mutations in LRRK2

Authors

  • Javier Ruiz-Martínez MD, PhD,

    Corresponding author
    1. Department of Neurology, University Hospital Donostia, San Sebastián, Spain
    2. Center for Biomedical Research in Neurodegenerative Diseases Network (CIBERNED), San Sebastián, Spain
    3. Neurosciences Area, Biodonostia Institute, San Sebastián, Spain
    • Correspondence to: Dr. Javier Ruiz-Martínez, Neurology Department, University Hospital Donostia, Paseo Dr Beguiristain s/n, 20014 Donostia, San Sebastián, Gipuzkoa, Spain; javier.ruizmartinez@osakidetza.net

    Search for more papers by this author
  • Patricia de la Riva MD,

    1. Department of Neurology, University Hospital Donostia, San Sebastián, Spain
    Search for more papers by this author
  • Maria C. Rodríguez-Oroz MD, PhD,

    1. Neurosciences Area, Biodonostia Institute, San Sebastián, Spain
    Search for more papers by this author
  • Elisabet Mondragón Rezola MD,

    1. Department of Neurology, University Hospital Donostia, San Sebastián, Spain
    2. Center for Biomedical Research in Neurodegenerative Diseases Network (CIBERNED), San Sebastián, Spain
    Search for more papers by this author
  • Alberto Bergareche MD,

    1. Department of Neurology, University Hospital Donostia, San Sebastián, Spain
    2. Center for Biomedical Research in Neurodegenerative Diseases Network (CIBERNED), San Sebastián, Spain
    3. Neurosciences Area, Biodonostia Institute, San Sebastián, Spain
    Search for more papers by this author
  • Ana Gorostidi PhD,

    1. Center for Biomedical Research in Neurodegenerative Diseases Network (CIBERNED), San Sebastián, Spain
    2. Neurosciences Area, Biodonostia Institute, San Sebastián, Spain
    Search for more papers by this author
  • Belen Gago PhD,

    1. Center for Biomedical Research in Neurodegenerative Diseases Network (CIBERNED), San Sebastián, Spain
    2. Neurosciences Area, Biodonostia Institute, San Sebastián, Spain
    Search for more papers by this author
  • Ainara Estanga,

    1. Department of Neurology, University Hospital Donostia, San Sebastián, Spain
    Search for more papers by this author
  • Nerea Larrañaga MD, PhD,

    1. Public Health Department of Gipuzkoa, Basque Government, San Sebastián, Spain
    2. Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), San Sebastián, Spain
    Search for more papers by this author
  • Cristina Sarasqueta MD, PhD,

    1. Epidemiology Area, Biodonostia Institute, San Sebastián, Spain
    2. Research Network for Health Services in Chronic Disease (REDISSEC), San Sebastián, Spain
    Search for more papers by this author
  • Adolfo López de Munain MD, PhD,

    1. Department of Neurology, University Hospital Donostia, San Sebastián, Spain
    2. Center for Biomedical Research in Neurodegenerative Diseases Network (CIBERNED), San Sebastián, Spain
    3. Neurosciences Area, Biodonostia Institute, San Sebastián, Spain
    4. Department of Neuroscience, University of the Basque Country (UPV-EHU), San Sebastián, Spain
    Search for more papers by this author
  • José F. Martí Massó MD, PhD

    1. Department of Neurology, University Hospital Donostia, San Sebastián, Spain
    2. Center for Biomedical Research in Neurodegenerative Diseases Network (CIBERNED), San Sebastián, Spain
    3. Neurosciences Area, Biodonostia Institute, San Sebastián, Spain
    Search for more papers by this author

  • Funding agencies: Ilundain Foundation, the Basque Government (Health Department: 2006111003); Center for Biomedical Research in Neurodegenerative Diseases Network (CIBERNED); Carlos III Health Institute (PI070660).

  • Relevant conflicts of interest/financial disclosures: Nothing to report.

  • Full financial disclosures and author roles may be found in the online version of this article.

ABSTRACT

An inverse relationship between Parkinson's disease (PD) and cancer has been described. However, the association between cancers and genetic forms of PD, in particular the R1441G mutation in the LRRK2 gene, is not well known. The objective of this work was to analyze cancer prevalence in PD patients with R1441G or G2019S mutations in LRRK2, and in idiopathic PD (iPD). A total of 732 patients with PD (70 and 25 carriers of R1441G or G2019S mutations, respectively), and 177 controls, were linked using a population-based cancer registry of the Spanish province of Gipuzkoa. Cancer prevalence was not significantly higher in PD-G2019S carriers (20%) than in PD-R1441G carriers (14.3%), iPD (13.8%), or controls (12.5%). With the exception of a high prevalence of hematological cancers (crude odds ratio of 7.1) in the R1441G group, specific cancer types were not increased in PD mutation carriers. In both the carrier and iPD groups, cancers were diagnosed after the onset of PD. PD patients had a similar prevalence of cancer to control subjects. There was no increased association between G2019S or R1441G mutations and any type of cancer. Although there was a higher prevalence of hematological cancers in the R1441G group, the low number of such cancers overall makes this finding of uncertain significance. There was a slightly higher but not statistically significant prevalence of non-skin cancers in the G2019S group, suggesting that further study to evaluate the association should be undertaken prior to ascribing an increased cancer risk to this population. © 2013 International Parkinson and Movement Disorder Society

Ancillary